A Multistep, Consensus-Based Approach to Organ Allocation in Liver Transplantation: Toward a "blended Principle Model"

American Journal of Transplantation

Volumn 15, Issue 10, 2015, Pages 2552-2561

  Cillo, U ^a   Burra, P ^a   Mazzaferro, V ^b   Belli, L ^c   Pinna, A D ^d   Spada, M ^e   Nanni Costa, A ^f   Toniutto, P ^g   Avolio, Alfonso ^h   Cescon, Matteo ^h   Regalia, Enrico ^h   Romagnoli, Renato ^h   Santaniello, Walter ^h   Rossi, Massimo ^h   Corno, Vittorio ^h   Caraceni, Paolo ^h   Coco, Barbara ^h   Fraquelli, Mirella ^h   Rendina, Maria ^h   Angelico, Mario ^h   Fagiuoli, Stefano ^h   Bruno, Raffaele ^h   Costa, Alessandro Nanni ^h   De Feo, Tullia ^h   Ridolfi, Lorenza ^h   Pretagostini, Renzo ^h   Amoroso, Antonio ^h   Biancofiore, Giandomenico ^h   De Gasperi, Andrea ^h   Della Rocca, Giorgio ^h   Feltracco, Paolo ^h   Colli, Agostino ^h   Sacchini, Dario ^h   Pegoraro, Renzo ^h   Gardini, Ivan ^h   more..

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

^f Italian National Transplant Center   (Italy)

^g UNIVERSITY OF UDINE   (Italy)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ALGORITHM; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CENTERS FOR DISEASE CONTROL GRADING SYSTEM; CONSENSUS; DISEASE COURSE; DONOR SELECTION; HEALTH CARE POLICY; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; ORGAN ALLOCATION; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENT DISEASE; SCORING SYSTEM; TIME; TRANSPLANT SURGEON; TUMOR VOLUME; CONSENSUS DEVELOPMENT; DECISION SUPPORT SYSTEM; HEALTH CARE ORGANIZATION; ITALY; LIVER DISEASES; PRACTICE GUIDELINE; SEVERITY OF ILLNESS INDEX; STANDARDS;

ALGORITHMS; DECISION SUPPORT TECHNIQUES; HEALTH CARE RATIONING; HUMANS; ITALY; LIVER DISEASES; LIVER TRANSPLANTATION; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX;

EID: 84941937152     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13408     Document Type: Article

References (33)

1. Schaubel DE, Guidinger MK, Biggins SW, et al., Survival benefit-based deceased-donor liver allocation. Am J Transplant 2009; 9: 970-981.
2. Freeman RB Jr, Gish RG, Harper A, et al., Model for end-stage liver disease (MELD) exception guidelines: Results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006; 12: S128-S136
3. Angelico M, Cillo U, Fagiuoli S, et al., Liver Match, a prospective observational cohort study on liver transplantation in Italy: Study design and current practice of donor-recipient matching. Dig Liver Dis 2011; 43: 155-164.
4. Toso C, Dupuis-Lozeron E, Majno P, et al., A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology 2012; 56: 149-156.
5. Vitale A, Morales RR, Zanus G, et al., Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: A multicentre, cohort study. Lancet Oncol 2011; 12: 654-662.
6. Avolio AW, Cillo U, Salizzoni M, et al., Balancing donor and recipient risk factors in liver transplantation: The value of D-MELD with particular reference to HCV recipients. Am J Transplant 2011; 11: 2724-2736.
7. Cholongitas E, Germani G, Burroughs AK,. Prioritization for liver transplantation. Nat Rev Gastroenterol Hepatol 2010; 7: 659-668.
8. Cillo U, Vitale A, Volk ML, et al., The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis 2010; 42: 642-649.
9. Mazzaferro V, Llovet JM, Miceli R, et al., Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
10. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA,. The survival benefit of liver transplantation. Am J Transplant 2005; 5: 307-313.
11. Navasa Bruix MJ,. Multifaceted perspective of the waiting list for liver transplantation: The value of pharmacokinetic models. Hepatology 2010; 51: 12-15.
12. Schaubel DE, Sima CS, Goodrich NP, Feng S, Merion RM,. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8: 419-425.
13. Atkins D, Best D, Briss PA, et al., Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
14. Toso C, Meeberg G, Hernandez-Alejandro R, et al., Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology 2015; [Epub ahead of print].
15. Yao FY, Ferrell L, Bass NM, et al., Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403.
16. Duvoux C, Roudot-Thoraval F, Decaens T, et al., Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986-994.
17. Vitale A, D'Amico F, Frigo AC, et al., Response to therapy as a criterion for awarding priority to patients with hepatocellular carcinoma awaiting liver transplantation. Ann Surg Oncol 2010; 17: 2290-2302.
18. Llovet JM, Di Bisceglie AM, Bruix J, et al., Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
19. Vitale A, Volk ML, De Feo TM, et al., A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol 2014; 60: 290-297.
20. Available from: http://www.eurotransplant.org/cms/index.php?page=et-manual.
21. Available from: http://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp.
22. Available from: http://odt.nhs.uk/transplantation/guidance-policies.
23. Available from: http://optn.transplant.hrsa.gov/resources/forums.asp.
24. Available from: http://www.ont.es/Documents/datos2014.pdf.
25. Kamath PS, Wiesner RH, Malinchoc M, et al., A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470.
26. Asrani SK, Kim WR, Heimbach JK,. Survival benefit of liver transplantation: One size fits all or fits none? Hepatology 2009; 50: 352-354.
27. Knight M, Barber K, Gimson A, Collett D, Neuberger J,. Implications of changing the minimal survival benefit in liver transplantation. Liver Transpl 2012; 18: 549-557.
28. Neuberger J,. Rationing life-saving resources-How should allocation policies be assessed in solid organ transplantation. Transpl Int 2012; 25: 3-6.
29. Persad G, Wertheimer A, Emanuel EJ,. Principles for allocation of scarce medical interventions. Lancet 2009; 373: 423-431.
30. Francoz C, Belghiti J, Castaing D, et al., Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system. Liver Transpl 2011; 17: 1137-1151.
31. Cucchetti A, Cescon M, Bigonzi E, et al., Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl 2011; 17: 1344-1354.
32. Otto G, Herber S, Heise M, et al., Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-1267.
33. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A,. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-e22.